[{"address1": "1500 Broadway", "address2": "Suite 1401", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "332 208 6102", "website": "https://www.nuvationbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.", "fullTimeEmployees": 203, "companyOfficers": [{"maxAge": 1, "name": "Dr. David T. Hung M.D.", "age": 65, "title": "Founder, President, CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1000605, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Hattersley Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 694558, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Liu M.D., Ph.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 677151, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philippe  Sauvage", "age": 46, "title": "Chief Financial Officer & Principal Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Moses  Makunje CPA", "age": 44, "title": "VP of Finance and Principal Accounting & Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Stephen  Dang", "title": "VP of Legal & Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy  Markel", "age": 58, "title": "Chief People Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David C. Hanley Ph.D.", "age": 53, "title": "Chief Technical Operations Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 586040, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry A. Wentworth", "age": 50, "title": "Chief Regulatory Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Sjogren", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.82, "open": 2.78, "dayLow": 2.69, "dayHigh": 2.875, "regularMarketPreviousClose": 2.82, "regularMarketOpen": 2.78, "regularMarketDayLow": 2.69, "regularMarketDayHigh": 2.875, "beta": 1.359, "forwardPE": -5.4117646, "volume": 1170301, "regularMarketVolume": 1170301, "averageVolume": 2181080, "averageVolume10days": 2843960, "averageDailyVolume10Day": 2843960, "bid": 2.74, "ask": 2.76, "bidSize": 3200, "askSize": 4000, "marketCap": 928924928, "fiftyTwoWeekLow": 1.43, "fiftyTwoWeekHigh": 4.16, "priceToSalesTrailing12Months": 429.66, "fiftyDayAverage": 2.6392, "twoHundredDayAverage": 2.87255, "currency": "USD", "enterpriseValue": 364055296, "floatShares": 233829593, "sharesOutstanding": 335567008, "sharesShort": 14071650, "sharesShortPriorMonth": 11324145, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0418, "heldPercentInsiders": 0.26847, "heldPercentInstitutions": 0.56109, "shortRatio": 5.52, "shortPercentOfFloat": 0.0587, "impliedSharesOutstanding": 336567008, "bookValue": 1.495, "priceToBook": 1.8461539, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -532280992, "trailingEps": -2.18, "forwardEps": -0.63, "enterpriseToRevenue": 168.388, "enterpriseToEbitda": -2.718, "52WeekChange": 0.79617834, "SandP52WeekChange": 0.2729931, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "NUVB", "underlyingSymbol": "NUVB", "shortName": "Nuvation Bio Inc.", "longName": "Nuvation Bio Inc.", "firstTradeDateEpochUtc": 1598448600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "292fc361-56ab-3994-b08a-1a4c45c2f81b", "messageBoardId": "finmb_639036735", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.76, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.5, "targetMedianPrice": 6.5, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 549134976, "totalCashPerShare": 1.632, "ebitda": -133927000, "totalDebt": 11192000, "quickRatio": 9.374, "currentRatio": 9.57, "totalRevenue": 2162000, "debtToEquity": 2.226, "revenuePerShare": 0.009, "returnOnAssets": -0.13976, "returnOnEquity": -0.95536005, "freeCashflow": -33288250, "operatingCashflow": -99140000, "grossMargins": -0.32377, "operatingMargins": -66.16369, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]